糖胺增强了20S蛋白质酶的活性和α-Synuclein的降解
Yusaku Sadahiro1, Soichiro Nishimura1, Yuki Hitora1
1Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.
Journal of natural products
|November 8, 2023
概括
氨酸激活了20S蛋白质组,增强了内在失调蛋白质 (IDP) 的降解. 这一发现提供了神经退行性疾病的潜在治疗策略,通过防止IDP积累.
科学领域:
- 生物化学 生化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 内在无序的蛋白质 (IDP) 积累和聚合,导致神经退行性疾病.
- 与26S蛋白质酶体不同的是,20S蛋白质酶体不像26S蛋白质酶体那样,独立于ATP和泛素降解IDP.
- 必须打开20S蛋白质组的门,以促进IDP的降解.
研究的目的:
- 为了确定增强20S蛋白酶体活性的化合物.
- 研究20S蛋白酶激活剂对神经退行性疾病的治疗潜力.
主要方法:
- 在普雷斯特威克植物化学图书馆选20S蛋白酶激活剂.
- 评估已识别的化合物对原基质和α-synuclein降解的影响.
- 使用HeLa细胞中的光探针来确认20S蛋白酶体门的打开.
主要成果:
- 鉴定出几种约因宾类型和藻类化物是20S蛋白酶体增强剂.
- 赛洛西诺成为最强大的激活剂,显著增强了IDP降解.
- 已证实,氨酸可以打开20S蛋白质酶门,从而促进基质的访问.
结论:
- 氨酸是20S蛋白酶体的强有力的激活剂.
- 开启20S蛋白酶体门的西罗斯平类化合物通过清除聚合的IDP来治疗神经退行性疾病具有前途.
相关概念视频
The Proteasome
855
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
855
The Proteasome Structure
773
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
773
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K


